Paris, France, and Fort Worth, Texas, United States, January 8, 2020 – Eyevensys, a privately held clinical-stage biotechnology company developing non-viral gene...
San Francisco, CA., October 11, 2019 – Eyevensys a private, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, this week...
Our approach is based on Eyevensys’ EyeCET platform, the first non-viral technology that allows reprogramming of the ciliary muscle cells for the production of well-known therapeutic proteins.
Eyevensys’ lead product, EYS606 is being developed as a potential new treatment for non-infectious uveitis. EYS606 has been granted an Orphan designation by the EMA for the treatment of NIU and is expected to enter into clinic imminently.
The EyeCET treatment procedure, which takes less than 5 minutes, is designed to provide the patient with a local and safe treatment with long lasting effects, between 3 and up to potentially 12 months.
Vision
Eyevensys’ vision is to harness our EyeCET platform to address major unfulfilled needs in the treatment of sight threatening ophthalmic diseases.
